The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
In order to evaluate the effect of CYP3A5*3 allele on the pharmacokinetics of sildenafil,
udenafil, and vardenafil, the clinical trial using a single oral dose was conducted in Korean
healthy male subjects whose genotype of CYP3A5 had been determined.